Hepatitis Monthly

Published by: Kowsar

Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review

Soheil Tavakolpour 1 , Seyed Moayed Alavian 1 , * and Shahnaz Sali 2
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqyiatallah University of Medical Sciences, Tehran, IR Iran
2 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: April 01, 2016, 16 (4); e35810
  • Published Online: March 26, 2016
  • Article Type: Review Article
  • Received: December 26, 2015
  • Revised: January 17, 2016
  • Accepted: January 27, 2016
  • DOI: 10.5812/hepatmon.35810

To Cite: Tavakolpour S, Alavian S M, Sali S. Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review, Hepat Mon. 2016 ; 16(4):e35810. doi: 10.5812/hepatmon.35810.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Immune System Response and Hepatitis B Virus Infection
3. Hepatitis B Virus Reactivation Definition
4. Conditions With the Risk of Hepatitis B Virus Reactivation
5. Risk Factors
6. Management of Patients With a Risk of Hepatitis B Virus Reactivation During Immunosuppressive Therapy or Chemotherapy
  • 1. Hepatitis B.
  • 2. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003; 70(4): 553-61[DOI][PubMed]
  • 3. Moses SE, Lim Z, Zuckerman MA. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2011; 9(10): 891-9[DOI][PubMed]
  • 4. Liao YP, Jiang JL, Zou WY, Xu DR, Li J. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. World J Gastroenterol. 2015; 21(14): 4284-92[DOI][PubMed]
  • 5. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association I. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015; 148(1): 215-9[DOI][PubMed]
  • 6. Hwang JP, Artz AS, Somerfield MR. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Oncol Pract. 2015; 11(4)-9[DOI][PubMed]
  • 7. European Association For The Study Of The L. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1): 167-85[DOI][PubMed]
  • 8. Said ZN, Abdelwahab KS. Induced immunity against hepatitis B virus. World J Hepatol. 2015; 7(12): 1660-70[DOI][PubMed]
  • 9. Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992; 16(1): 13-8[PubMed]
  • 10. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013): 44-9[DOI][PubMed]
  • 11. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010; 29(9): 1021-9[DOI][PubMed]
  • 12. Mewar D, Wilson AG. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol. 2011; 162(4): 785-91[DOI][PubMed]
  • 13. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med. 2000; 223(3): 241-57[PubMed]
  • 14. Kasahara S, Ando K, Saito K, Sekikawa K, Ito H, Ishikawa T, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol. 2003; 77(4): 2469-76[PubMed]
  • 15. Xu J, Zhang S, Zhang Z, Fu L, Zheng Q, Wang J, et al. TNF-alpha promoter region polymorphisms affect HBV virus clearance in southern Chinese. Clin Chim Acta. 2013; 425: 90-2[DOI][PubMed]
  • 16. Kao PC, Wu JF, Ni YH, Lin YT, Chen HL, Hsu SH, et al. Tumour necrosis factor-alpha promoter region polymorphisms affect the course of spontaneous HBsAg clearance. Liver Int. 2010; 30(10): 1448-53[DOI][PubMed]
  • 17. Zhang TC, Zhao YQ, Hu GL, Liu XQ, Huang XK. The relationship between tumour necrosis factor-alpha gene polymorphism and susceptibility and clearance of the persistent hepatitis B virus infection in a Chinese population: a meta-analysis. Clin Microbiol Infect. 2014; 20(3): 227-34[DOI][PubMed]
  • 18. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol. 2010; 184(1): 287-95[DOI][PubMed]
  • 19. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol. 2007; 85(1): 16-23[DOI][PubMed]
  • 20. Cao T, Lazdina U, Desombere I, Vanlandschoot P, Milich DR, Sallberg M, et al. Hepatitis B virus core antigen binds and activates naive human B cells in vivo: studies with a human PBL-NOD/SCID mouse model. J Virol. 2001; 75(14): 6359-66[DOI][PubMed]
  • 21. Wu SF, Wang WJ, Gao YQ. Natural killer cells in hepatitis B virus infection. Braz J Infect Dis. 2015; 19(4): 417-25[DOI][PubMed]
  • 22. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis. 2015; 6[DOI][PubMed]
  • 23. Tavakolpour S. The new insight into management of hepatitis B virus patients with flare. Immunology letters. 2016; : 173-77
  • 24. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100(1): 182-8[PubMed]
  • 25. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009; 50(3): 661-2[DOI][PubMed]
  • 26. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood. 2002; 100(2): 391-6[PubMed]
  • 27. Lau GK, Leung YH, Fong DY, Au WY, Kwong YL, Lie A, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002; 99(7): 2324-30[PubMed]
  • 28. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009; 27(4): 605-11[DOI][PubMed]
  • 29. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125(6): 1742-9[PubMed]
  • 30. UyanikoGLu A, Sert U, Nar H, YenİCe N. Occult Hepatitis B Reactivation After Chemoteraphy: A Case Report. Viral Hepatit Dergisi. 2015; 21(2): 56-8[DOI]
  • 31. Du W, Zheng Z, Han S, Ma S, Chen S. HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review. BMC Infect Dis. 2013; 13: 394[DOI][PubMed]
  • 32. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med. 2006; 45(11): 721-4[PubMed]
  • 33. Ghrenassia E, Mekinian A, Rouaghe S, Ganne N, Fain O. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2012; 79(1): 100-1[DOI][PubMed]
  • 34. Feeney SA, McCaughey C, Watt AP, Agnaf MR, McDougall N, Wend UC, et al. Reactivation of occult hepatitis B virus infection following cytotoxic lymphoma therapy in an anti-HBc negative patient. J Med Virol. 2013; 85(4): 597-601[DOI][PubMed]
  • 35. Lee HJ, Kim DY, Keam B, Lee JH, Han SW, Oh DY, et al. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy. Breast Cancer. 2014; 21(4): 387-93[DOI][PubMed]
  • 36. Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011; 104(4): 559-63[DOI][PubMed]
  • 37. Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004; 88(3): 209-15[DOI][PubMed]
  • 38. Yang Y, Du Y, Luo WX, Li C, Chen Y, Cheng K, et al. Hepatitis B virus reactivation and hepatitis in gastrointestinal cancer patients after chemotherapy. Cancer Chemother Pharmacol. 2015; 75(4): 783-90[DOI][PubMed]
  • 39. Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol. 2014; 20(24): 7675-85[DOI][PubMed]
  • 40. Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma. 2006; 47(1): 155-7[DOI][PubMed]
  • 41. Wang YD, Cui GH, Li M, Gowrea B, Xia J, Hu Y. Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate. Chin Med J (Engl). 2012; 125(14): 2636-7[PubMed]
  • 42. Dixon WG, Kezouh A, Bernatsky S, Suissa S. The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis. 2011; 70(6): 956-60[DOI][PubMed]
  • 43. Nobili L, Albani L, Gabrielli A, Moroncini G. Reactivation of Hepatitis B Virus Infection Associated with Anti-Tumor Necrosis Factor-a Therapy. J Antivir Antiretrovir. 2014; (6): 92-101
  • 44. Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol. 2012; 31(6): 931-6[DOI][PubMed]
  • 45. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011; 46(4): 556-64[DOI][PubMed]
  • 46. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2011; 70(10): 1719-25[DOI][PubMed]
  • 47. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, Lopez-Roses L, Brito-Zeron P, Perez-de-Lis M, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011; 90(6): 359-71[DOI][PubMed]
  • 48. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int. 2011; 31(3): 403-4[DOI][PubMed]
  • 49. Salman-Monte TC, Lisbona MP, Garcia-Retortillo M, Maymo J. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin. 2014; 10(3): 196-7[DOI][PubMed]
  • 50. Ceneli O, Ozkurt ZN, Acar K, Rota S, Aki SZ, Yegin ZA, et al. Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients. World J Gastroenterol. 2010; 16(14): 1765-71[PubMed]
  • 51. Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009; 15(9): 1049-59[DOI][PubMed]
  • 52. Lin PC, Poh SB, Lee MY, Hsiao LT, Chen PM, Chiou TJ. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol. 2005; 81(4): 349-51[DOI][PubMed]
  • 53. Uhm JE, Kim K, Lim TK, Park BB, Park S, Hong YS, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007; 13(4): 463-8[DOI][PubMed]
  • 54. Yoo JJ, Cho EJ, Cho YY, Lee M, Lee DH, Cho Y, et al. Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. Liver Int. 2015; 35(12): 2530-6[DOI][PubMed]
  • 55. Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation. 2005; 79(11): 1631-3[PubMed]
  • 56. Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola AM, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infect. 2014; 20(10)-701[DOI][PubMed]
  • 57. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. Clin Infect Dis. 2005; 41(9): 1277-82[DOI][PubMed]
  • 58. Blanpain C, Knoop C, Delforge ML, Antoine M, Peny MO, Liesnard C, et al. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies: report on three cases and review of the literature. Transplantation. 1998; 66(7): 883-6[PubMed]
  • 59. Levitsky J, Doucette K, A. S. T. Infectious Diseases Community of Practice . Viral hepatitis in solid organ transplantation. Am J Transplant. 2013; 13 Suppl 4: 147-68[DOI][PubMed]
  • 60. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15(10): 1143-238[DOI][PubMed]
  • 61. Nakamoto S, Kanda T, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci. 2014; 15(11): 21455-67[DOI][PubMed]
  • 62. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology. 1993; 18(6): 1313-8[PubMed]
  • 63. Kim MK, Ahn JH, Kim SB, Im YS, Lee SI, Ahn SH, et al. Hepatitis B reactivation during adjuvant anthracycline-based chemotherapy in patients with breast cancer: a single institution's experience. Korean J Intern Med. 2007; 22(4): 237-43[PubMed]
  • 64. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010; 11(9): 827-34[DOI][PubMed]
  • 65. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Takasaki H, et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin Infect Dis. 2015; 61(5): 719-29[DOI][PubMed]
  • 66. Kim E, Yune S, Ha JM, Lee WJ, Hwang JW, Paik YH, et al. Hepatitis B virus reactivation during anti-cancer chemotherapy in patients with past hepatitis B virus infection. Hepatogastroenterology. 2014; 61(134): 1704-11[PubMed]
  • 67. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014; 32(33): 3736-43[DOI][PubMed]
  • 68. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011; 90(10): 1219-23[DOI][PubMed]
  • 69. Mozessohn L, Chan KK, Feld JJ, Hicks LK. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015; 22(10): 842-9[DOI][PubMed]
  • 70. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62(3): 299-307[PubMed]
  • 71. Shao W, Zhang F, Cong N, Li J, Song J. The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level. Ther Clin Risk Manag. 2015; 11: 1367-70[DOI][PubMed]
  • 72. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90(7): 1306-11[DOI][PubMed]
  • 73. Borentain P, Colson P, Coso D, Bories E, Charbonnier A, Stoppa AM, et al. Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer. J Viral Hepat. 2010; 17(11): 807-15[DOI][PubMed]
  • 74. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol. 2004; 15(11): 1661-6[DOI][PubMed]
  • 75. Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol. 2013; 58(2): 396-400[DOI][PubMed]
  • 76. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK. Hepatitis B infection in patients with lymphomas. Hematol Oncol. 1990; 8(5): 261-70[PubMed]
  • 77. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004; 83(5): 270-5[DOI][PubMed]
  • 78. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008; 47(3): 844-53[DOI][PubMed]
  • 79. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003; 37(6): 1320-8[DOI][PubMed]
  • 80. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis. 2013; 16(5): 527-31[DOI][PubMed]
  • 81. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2010; 69(7): 1352-5[DOI][PubMed]
  • 82. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009; 49(5 Suppl)-60[DOI][PubMed]
  • 83. Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia. 2013; 17(1): 91-3[PubMed]
  • 84. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med. 2001; 344(1): 68-9[DOI][PubMed]
  • 85. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011; 22(5): 1170-80[DOI][PubMed]
  • 86. Mitroulis I, Hatzara C, Kandili A, Hadziyannis E, Vassilopoulos D. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013; 72(2): 308-10[DOI][PubMed]
  • 87. van Vollenhoven RF, Fleischmann RM, Furst DE, Lacey S, Lehane PB. Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years. J Rheumatol. 2015; 42(10): 1761-6[DOI][PubMed]
  • 88. Di Bisceglie AM, Lok AS, Martin P, Terrault N, Perrillo RP, Hoofnagle JH. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015; 61(2): 703-11[DOI][PubMed]
  • 89. Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, et al. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies. Eur J Intern Med. 2014; 25(5): 482-4[DOI][PubMed]
  • 90. Ballanti E, Conigliaro P, Chimenti MS, Kroegler B, Di Muzio G, Guarino MD, et al. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res. 2014; 75 Suppl 1-5[DOI][PubMed]
  • 91. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2009; 36(11): 2416-20[DOI][PubMed]
  • 92. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003; 62(7): 686-7[PubMed]
  • 93. Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology. 2009; 49(5 Suppl)-44[DOI][PubMed]
  • 94. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012; 6(3): 531-61[DOI][PubMed]
  • 95. Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, et al. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc. 2015; 114(2): 164-73[DOI][PubMed]
  • 96. Li H, Zhang HM, Chen LF, Chen YQ, Chen L, Ren H, et al. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015; 39(1): 80-92[DOI][PubMed]
  • 97. Liu HL, Zhao Z, Yang H, Liu FF, Liu Q, Luo Q, et al. The effects of nucleoside analogue prophylactic treatment on HBV activation in HBcAb+ patients undergoing immunosuppressive therapy. J Viral Hepat. 2013; 20(9): 645-9[DOI][PubMed]
  • 98. Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int. 2013; 33(8): 1203-10[DOI][PubMed]
  • 99. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014; 312(23): 2521-30[DOI][PubMed]
  • 100. Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, et al. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014; 58(3): 1730-7[DOI][PubMed]
  • 101. Yatsuji H, Suzuki F, Sezaki H, Akuta N, Suzuki Y, Kawamura Y, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol. 2008; 48(6): 923-31[DOI][PubMed]
  • 102. van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004; 40(6): 1421-5[DOI][PubMed]
  • 103. Koskinas JS, Deutsch M, Adamidi S, Skondra M, Tampaki M, Alexopoulou A, et al. The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center. Eur J Intern Med. 2014; 25(8): 768-71[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments